# US 11,246,922 B1 · Vaccine RNA-peptide against SARS-CoV-2 with endogenous exosomes as carrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,246,922 B1
- Document ID: US11246922B1
- Status: Granted
- Kind: B1
- Application number: 17/245,535
- Filed: 2021-04-30
- Granted: 2022-02-15
- Earliest claimed: 2021-04-30
- Assignees: Elidan America, LLC.
- Applicants: Elidan America, LLC.
- Inventors: Luis Cruz Rodriguez
- Web page: https://patentgrep.com/patent/US11246922B1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 38/45: Transferases (2)
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/6025: {Nucleotides}
- A61K 2039/6031: {Proteins}
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccine RNA-peptide against SARS-CoV-2, which has a messenger ribonucleic acid (mRNA) having an open reading frame encoding a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein. The peptide of the severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein is fused to a synthetic poly ADP-ribose polymerase peptide. The vaccine RNA-peptide against SARS-CoV-2 has endogenous exosomes as carrier.

## Claims

### Claim 1

A composition against SARS-CoV-2, comprising a micro ribonucleic acid (miRNA) fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein having an amino acid sequence of SEQ ID NO: 2 wherein endogenous exosomes act as carrier.

### Claim 2 (depends on 1)

The composition against SARS-CoV-2 according to claim 1, wherein the miRNA comprises a poly-A sequence.

### Claim 3 (depends on 1)

The composition against SARS-CoV-2 according to claim 1, wherein the poly-A sequence is about 10 adenosine nucleotides.

### Claim 4 (depends on 1)

The composition against SARS-CoV-2 according to claim 1, wherein the miRNA comprises the nucleic acid sequence of SEQ ID NO: 1.

### Claim 5 (depends on 1)

The composition against SARS-CoV-2 according to claim 1, wherein the peptide of the SARS-CoV-2 surface protein of SEQ ID: 2 is fused to a synthetic poly ADP-ribose polymerase peptide.

### Claim 6 (depends on 1)

A method for stimulating an immune response against SARS-CoV-2 in a subject comprising administering to said subject an effective amount of the composition of claim 1.

### Claim 7

A composition against SARS-CoV-2, comprising a micro ribonucleic acid (miRNA) fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein having the amino acid sequence of SEQ ID NO: 2 fused to a synthetic poly ADP-ribose polymerase peptide.

### Claim 8 (depends on 7)

The composition against SARS-CoV-2 according to claim 7, wherein the miRNA comprises a poly-A sequence.

### Claim 9 (depends on 7)

The composition against SARS-CoV-2 according to claim 7, wherein the poly-A sequence is about 10 adenosine nucleosides.

### Claim 10 (depends on 7)

The composition against SARS-CoV-2 according to claim 7, wherein the miRNA comprises the nucleic acid sequence of SEQ ID NO: 1.

### Claim 11 (depends on 7)

The composition against SARS-CoV-2 according to claim 7, wherein the synthetic poly ADP-ribose polymerase peptide comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 12 (depends on 7)

The composition against SARS-CoV-2 according to claim 7, wherein the micro ribonucleic acid (miRNA) is fused to a peptide that comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 13 (depends on 7)

A method for stimulating an immune response against SARS-CoV-2 in a subject in need thereof comprising administering to said subject an effective amount of the composition of claim 7.

### Claim 14

A composition against SARS-CoV-2 comprising a micro ribonucleic acid (miRNA) having a nucleic acid sequence of SEQ ID NO: 1 fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein fused to a synthetic poly ADP-ribose polymerase peptide that comprises the amino acid sequence of SEQ ID NO: 4, wherein endogenous exosomes act as carrier.